Bioenvision to Host Third Quarter 2006 Financial Results Conference Call

To participate in the live call by telephone, please dial877-715-5320 from the U.S. and Canada or 973-582-2853 from outside theU.S. A telephone replay of the call will be available beginning at12:00 p.m. EST May 15th until 11:59 p.m. EST May 29th by dialing877-519-4471 or 973-341-3080 and entering reservation number 7373873.

Those interested in listening to the conference call live via theInternet may do so by visiting www.vcall.com where a link toBioenvision's conference call can be found. Please go to the web site15 minutes prior to its start to register, download, and install thenecessary audio software. A replay will be available for 14 days.

About Bioenvision

Bioenvision's primary focus is the acquisition, development anddistribution of compounds and technologies for the treatment ofcancer. Bioenvision has a broad pipeline of products for the treatmentof cancer, including: Clofarabine (in co-development with GenzymeCorporation), Modrenal(R) (for which Bioenvision has obtainedregulatory approval for marketing in the United Kingdom for thetreatment of post-menopausal breast cancer following relapse toinitial hormone therapy), and other products in clinical trials.Bioenvision is also developing anti-infective technologies, includingSuvus for hepatitis-C and the OLIGON technology; an advancedbiomaterial that has been incorporated into various FDA approvedmedical devices. For more information on Bioenvision please visit ourweb site at www.bioenvision.com.

Certain statements contained herein are "forward-looking"statements (as such term is defined in the Private SecuritiesLitigation Reform Act of 1995). Because these statements include risksand uncertainties, actual results may differ materially from thoseexpressed or implied by such forward-looking statements. Specifically,factors that could cause actual results to differ materially fromthose expressed or implied by such forward-looking statements include,but are not limited to: risks associated with preclinical and clinicaldevelopments in the biopharmaceutical industry in general and inBioenvision's compounds under development in particular; the potentialfailure of Bioenvision's compounds under development to prove safe andeffective for treatment of disease; uncertainties inherent in theearly stage of Bioenvision's compounds under development; failure tosuccessfully implement or complete clinical trials; failure to receivemarketing clearance from regulatory agencies for our compounds underdevelopment; acquisitions, divestitures, mergers, licenses orstrategic initiatives that change Bioenvision's business, structure orprojections; the development of competing products; uncertaintiesrelated to Bioenvision's dependence on third parties and partners; andthose risks described in Bioenvision's filings with the SEC.Bioenvision disclaims any obligation to update these forward-lookingstatements.